Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gama Explorations, Inc. ( (TSE:SKNY) ) just unveiled an update.
LIR Life Sciences Corp. has filed a provisional patent application for a needle-free delivery platform for GLP/GIP-based therapies targeting obesity and metabolic diseases. This initiative is part of LIR’s broader strategy to develop a versatile platform compatible with existing and future GLP- and GIP-based medicines, potentially improving patient adherence and expanding access to treatments by reducing the need for injections.
More about Gama Explorations, Inc.
LIR Life Sciences is focused on researching and developing scalable and affordable treatments for obesity using novel drug delivery methods. The company is advancing a transdermal patch and other novel delivery systems that mimic GLP-1, a naturally occurring hormone that helps regulate appetite and blood sugar. These therapies could potentially offer an alternative to injectable drugs. The goal is to improve access, adherence, and cost-efficiency in both developed and emerging markets. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.
Average Trading Volume: 91,529
Technical Sentiment Signal: Strong Buy
For an in-depth examination of SKNY stock, go to TipRanks’ Overview page.